TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.150nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 10.4nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 20.6nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 21.7nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 25.3nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 28.1nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 56.4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 75nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 79.3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 142nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 177nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 209nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 233nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 281nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3 (N=1)More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 965nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.47E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.81E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.52E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.85E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.03E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.26E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4.36E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.20E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.61E+3nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha IIb beta-3 (N=1)More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.09E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.57E+4nMAssay Description:Inhibition of human Biotinylated Fg binding to immobilized Alpha II beta-3More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of human vitronectin binding to immobilized Alpha v beta-3More data for this Ligand-Target Pair